Nová antivirotika v léčbě hepatitidy C

Title in English New antivirotics in the treatment of hepatitis C
Authors

HUSA Petr

Year of publication 2014
Type Article in Periodical
Magazine / Source Praktické lékárenství
MU Faculty or unit

Faculty of Medicine

Citation
Field Epidemiology, infectious diseases and clinical immunology
Keywords hepatitis C; pegylated interferon; ribavirin; boceprevir; telaprevir; sofosbuvir; simeprevir
Description Treatment of chronic hepatitis C is undergoing extraordinary changes in the past 3 years. Direct-Acting Antiviral Agents (DAAs) are gradually introducing into routine clinical practice either in combination with pegylated interferon and ribavirin, or in interferon-free regimes. Boceprevir and telaprevir have been approved in the Czech Republic since 2012. Sobosbuvir and simeprevir have been available in the United States since the end of 2013, as well.

You are running an old browser version. We recommend updating your browser to its latest version.

More info